Pfizer touts late-stage vaccine success; Northwest Bio temporarily suspends patient screening;

@FierceBiotech: ICYMI Friday: Takeda rolls toward EU approval with its heir to Velcade. Story | Follow @FierceBiotech

@JohnCFierce: AstraZeneca lures Bohen from Genentech to fill R&D post vacated by Morrison. Report | Follow @JohnCFierce

> Pfizer ($PFE) reported Friday that its meningitis B vaccine Trumenba successfully hit its primary endpoints in two late-stage studies. Story

> Shares of Northwest Biotherapeutics ($NWBO) plunged on Friday as word spread around social media circles that the European clinical trial registry had listed a closely-watched study of their DCVax for glioblastoma as "temporarily halted." The Bethesda, MD-based biotech says that investigators had stopped screening new patients in order to submit new information for regulatory review, but that more than 300 patients already recruited for the study continued to receive treatment. Release

> Intrexon ($XON) raised $200 million from the sale of its stock. Release

Medical Device News

@FierceMedDev: DARPA-backed Wyss Institute sepsis device being readied for human trials. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Edge files for up to $115M IPO to support locally delivered med for brain aneurysms. Report | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Olympus duodenoscopes linked to suspected superbug outbreak at California hospital. More | Follow @EmilyWFierce

> Bayer's Grants4Apps accelerator funds its second crop of digital health startups. Story

> Micro-cap TriVascular starts post-market registry trial as it raises $10M. Article

Pharma News

@FiercePharma: ICYMI Friday: Novartis shells out up to $1B to test GSK's Arzerra in MS. Item | Follow @FiercePharma

@EricPFierce: Email exchange with Merck CEO posted by union shows frustrations over job cuts, double shifts. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Novartis places $1B bet to push CLL med Arzerra into MS fray. FiercePharmaMarketing story | Follow @CarlyHFierce

> Analysts: Gilead's hep C scripts keep slowing, and Q3 sales forecasts should too. More

> Takeda takes unexpected blow as blockbuster Velcade patent ruled invalid. Story

> Powerful cancer alliance joins cost-effectiveness drug crusade. Report

Animal Health News

> Report: Dietary supplements gaining popularity as aging dogs fight arthritis. Report

> Free of Zoetis, Sweden's Oasmia hits the road to pitch IPO. Article

> USDA solicits bids for bird flu vaccine production plan. Item

> Beef producers lash out at USDA's choice of Humane Society vet for advisory panel. Story

> Petco files for IPO, emphasizing focus on animal health. News

Biotech IT News

> Biogen taps ice bucket cash to build ALS database. More

> Life science unit graduates from Google X to become standalone business. News

> Intel makes pitch to become a hub for cancer data sharing. Report

> Flatiron teams with Guardant to mine blood test data for cancer R&D. Story

> Illumina teams with VCs to place $100M bet on consumer genomics. Article

Pharma Marketing News

> Janssen's new Prezcobix push urges HIV patients to share pics with their docs. Story

> Novartis places $1B bet to push CLL med Arzerra into MS fray. Report

> Medivation snaps up BioMarin's late-stage breast cancer med in $410M-plus deal. Item

> Sure, there's an app for that, but few top pharma apps get most of the attention. More

> Purdue hones abuse-deterrent edge with painkiller safety campaign. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.